Myofibroblast Origins and Activation: Drug Target Guide

Fibroblasts and Myofibroblasts: The "Architects" of Fibrosis

"Why won't myofibroblasts die?"—this question holds the key to drug discovery.

In normal wound healing, myofibroblasts disappear via apoptosis after doing their job. But in fibrotic tissue, they persist, churning out collagen indefinitely. "Kill them" or "silence them"—this strategic choice is the focus of anti-fibrotic drug discovery. This article dives deep into the diverse origins and activation maintenance mechanisms of myofibroblasts.

1. What are Myofibroblasts?

Definition and Characteristics

Myofibroblasts are cells with intermediate properties between Fibroblasts and Smooth Muscle Cells.

• Contractility: Contract like smooth muscle to physically shrink wounds (Wound Contraction).
• Vigorous ECM Production: Produce far greater amounts of collagen and fibronectin than normal fibroblasts.
• Marker: Expression of α-SMA (Alpha-Smooth Muscle Actin) is the most common indicator. Supporting markers include Vimentin (a pan-mesenchymal marker used to distinguish from epithelial cells) and CD90/Thy-1 (highly expressed in activated fibroblasts, correlating with the more contractile myofibroblast subset), which are frequently employed in preclinical evaluation.

Role: A Double-Edged Sword

• Normal Healing: Close wounds, create a scaffold (ECM), and disappear via apoptosis when healing is complete.
• Fibrotic Disease: Remain after healing (apoptosis resistance), continue to produce excessive ECM, making organs stiff and dysfunctional.

2. Where Do They Come From? (Diversity of Origins)

The origin of myofibroblasts is not single. Recent lineage tracing studies have revealed diverse roots.

1. Resident Fibroblasts

• The major source. Fibroblasts originally present in the tissue activate and transform.

2. Pericytes

• Cells surrounding blood vessels. Detaching from vessels and differentiating into myofibroblasts is considered important, especially in kidney and lung fibrosis.

3. Epithelial-Mesenchymal Transition (EMT)

• A phenomenon where epithelial cells lose their properties and change into mesenchymal cells (fibroblast-like).
• Once thought to be a major source, recent studies have re-evaluated its role as creating an environment (promoting fibrosis) via paracrine factors rather than direct differentiation into myofibroblasts.

4. Bone Marrow-Derived Cells (Fibrocytes)

• Progenitor cells that migrate to the injury site via the bloodstream.

3. Activation Mechanisms: Why Do They Go Out of Control?

TGF-β Signaling: The Strongest Driver

• TGF-β1 is the most potent cytokine that differentiates fibroblasts into myofibroblasts.
• Directly turns on gene expression of α-SMA and collagen via the TGF-β/Smad pathway.

Mechanotransduction (Sensing Stiffness)

• Vicious Cycle of "Stiffness Begets Stiffness": Fibroblasts have the ability to sense the stiffness of the scaffold (ECM).
• When tissue becomes stiff, mechanosensors like YAP/TAZ translocate into the nucleus, causing further activation. It is known that a stiff environment alone can promote myofibroblast differentiation even without TGF-β.

FAP (Fibroblast Activation Protein)

• A surface enzyme specifically expressed in activated fibroblasts (especially Cancer-Associated Fibroblasts CAFs and fibrosis sites).
• May label a different subset than α-SMA, attracting attention as a new therapeutic target.

PDGFR-β (Platelet-Derived Growth Factor Receptor β)

• A marker highly expressed in pericytes and mesenchymal progenitor cells, used to distinguish them from resident fibroblasts by lineage.
• In kidney, liver, and lung fibrosis models, it serves as a key indicator for identifying pericyte-derived myofibroblasts, and the PDGF-BB/PDGFR-β axis is also under investigation as an anti-fibrotic target. Because senescence of activated fibroblasts contributes to pathology, senolytics that clear senescent cells are another emerging strategy.

FSP-1 / S100A4 (Fibroblast-Specific Protein 1)

• A calcium-binding protein upregulated in activated fibroblasts and EMT cells. However, because it is also expressed in immune cells, its specificity is low, and caution is required when used alone to identify myofibroblasts.
• It is most useful for tracking EMT-derived cells when combined with other markers (co-staining with α-SMA and Vimentin).

Periostin

• An extracellular matrix protein expressed in a subset of myofibroblasts, particularly those with high TGF-β responsiveness.
• Periostin-positive myofibroblasts show strong localization to lesion sites in IPF (idiopathic pulmonary fibrosis) and other lung fibrosis models, with growing interest in its application as a disease progression indicator.

4. Therapeutic Application: How to Stop Them?

Deactivation / Reversion

• Attempts to return myofibroblasts to their original quiet fibroblast state.
• Rho kinase inhibitors and YAP/TAZ inhibitors are being researched.

Induction of Apoptosis

• Ordering "death" to the lingering myofibroblasts.
• Bcl-2 inhibitors and others are being researched in the context of senolysis (removal of senescent cells).

Conclusion

Fibroblasts and myofibroblasts are the execution unit of fibrosis. Their origins and activation mechanisms are complex, but understanding markers like α-SMA and FAP, and control pathways like TGF-β and Mechanotransduction, is essential for selecting drug discovery targets. In preclinical models, it is essential to establish efficacy evaluation systems using a multi-marker panel—α-SMA, FAP, PDGFR-β, FSP-1/S100A4, Periostin, Vimentin, and CD90—and to select the optimal assay system matched to the compound's mechanism of action (MOA).

Related Articles

• TGF-β/Smad Pathway — Signaling mechanisms of TGF-β, the master regulator of fibrosis
• YAP/TAZ Mechanotransduction — Hippo pathway and YAP/TAZ-mediated mechanical signal regulation
• Wnt/β-catenin Pathway — Wnt signaling involved in fibroblast proliferation and differentiation
• The Complete Guide to Fibrosis Mechanisms — Systematic overview of fibrosis pathology

---

References

1. Hinz B, et al. The myofibroblast: one function, multiple origins. Am J Pathol. 2007;170(6):1807-1816.
2. Klingberg F, et al. The myofibroblast matrix: implications for tissue repair and fibrosis. J Pathol. 2013;229(2):298-309.
3. Pakshir P, et al. The myofibroblast at a glance. J Cell Sci. 2020;133(13):jcs227900.
4. Kramann R, et al. Perivascular Gli1+ progenitors are key contributors to injury-induced organ fibrosis. Cell Stem Cell. 2015;16(1):51-66.
5. Zuo W, et al. Periostin promotes liver fibrosis through the activation of hepatic stellate cells. Sci Rep. 2020;10(1):13595.